Diabetes and Obesity: Phosphodiesterases
 | | | | | | | cAMP and cGMP, two important second messengers molecules are hydrolyzed by phosphodiesterases (PDEs) in the cell, leading to cessation of cAMP and cGMP-dependent effects. Due to their involvement in inflammation, asthma, and cardiovascular complications, erectile dysfunctions, PDEs are considered to be attractive targets for pharmacological intervention. Erectile dysfunction is a common multi-factorial complication of diabetes mellitus and PDE V inhibitor therapy has been found to be effective in special clinical populations, such as those with prostate cancer, diabetes, and cardiovascular disease. | | | | Antibodies |
|
|
|
|
|
| Anti-Phosphodiesterase V Rabbit pAb |
IB, IP |
bovine |
524583 |
|
| | | | Phosphodiesterases |
|
|
|
| Phosphodiesterase 11A1, Active, Human, Recombinant, S. frugiperda |
524735 |
| Phosphodiesterase 1A3, Human, Recombinant, S. frugiperda |
524740 |
| Phosphodiesterase 3B, Human, Recombinant, S. frugiperda |
524734 |
| Phosphodiesterase 3A1, Catalytic Domain, Human, Recombinant, S. frugiperda |
534736 |
| Phosphodiesterase 4A4, Human, Recombinant, S. frugiperda |
524731 |
| Phosphodiesterase 4B2, Human, Recombinant, S. frugiperda |
524736 |
| Phosphodiesterase 4B2, Catalytic Domain, His•Tag®, Human, Recombinant, S. frugiperda |
524732 |
| Phosphodiesterase 4C2, Human, Recombinant, S. frugiperda |
524737 |
| Phosphodiesterase 4D3, Human, Recombinant, S. frugiperda |
524733 |
| Phosphodiesterase 5, Catalytic Domain, Human, Recombinant, S. frugiperda |
524738 |
| Phosphodiesterase, Type II, Calf Spleen |
524711 |
| Phosphodiesterase, Type V, cGMP-Specific, Bovine, Recombinant, Spodoptera frugiperda |
524715 |
|
| | | | Phosphodiesterase V Inhibitors |
|
|
|
| Dipyridamole |
322328 |
| 3-Isobutyl-1-methylxanthine |
410957 |
| 4-{[3′,4′-(Methylenedioxy)benzyl]amino}-6-methoxyquinazoline |
475250 |
| MY-5445 |
474925 |
| Phosphodiesterase V Inhibitor II |
524714 |
| Zaprinast |
684500 |
|
| | | | Phosphodiesterase Substrates |
|
|
|
| Adenosine 3′,5′-cyclic Monophosphate, 2′-O-(N-Methylanthraniloyl)-, Sodium Salt |
116806 |
| Guanosine 3′,5′-cyclic Monophosphate, 2′-O-(N-Methylanthraniloyl)-, Sodium Salt |
370668 |
|
| | | | | |
 |
 |
|
